A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation (CARDIOVERT)
A Placebo-controlled, Parallel-group, Double Blind, Randomized, Multi-cohort Phase 2 Study to Investigate Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BAY 3670549 in Adult Participants With Atrial Fibrillation.
The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called electrical cardioversion.
Electrical cardioversion is a procedure that helps the heart return to a normal rhythm. In this study, each participant will get a single intravenous (IV) infusion of either BAY 3670549 or a placebo. Participants will then be observed to see whether the heart rhythm returns to a normal rhythm. If it does not, electrical cardioversion can still be performed as planned. The study will look at how many participants return from AF to a normal rhythm, without needing electrical cardioversion and how long it takes. It will also show how many participants experience medical problems after treatment and how BAY 3670549 move into, through and out of the participants' body.
The total duration of the study for an individual participant may be up two months.
The findings from this study may contribute to the development of a new treatment option for people with AF.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Bayer Clinical Trials Contact
- Telefonnummer: 18888422937
- E-Mail: clinical-trials-contact@bayer.com
Studienorte
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, Belgien, 3000
- Rekrutierung
- UZ Leuven Gasthuisberg - Cardiology diseases department
-
-
Limburg
-
Hasselt, Limburg, Belgien, 3500
- Noch keine Rekrutierung
- Jessa Ziekenhuis | Hartcentrum Hasselt
-
-
West Flanders
-
Roeselare, West Flanders, Belgien, 8800
- Noch keine Rekrutierung
- AZ Delta | Clinical Trial Center - Cardiology
-
-
-
-
Plovdiv Province
-
Plovdiv, Plovdiv Province, Bulgarien, 4001
- Noch keine Rekrutierung
- University Multiprofile Hospital For Active Treatment Sveti Georgi' - EAD Department of Intensive Cardiology"
-
-
Sofia City Province
-
Sofia, Sofia City Province, Bulgarien, 1233
- Noch keine Rekrutierung
- Multiprofile Hospital for Active Treatment Knyaginya Klementina Sofia EAD | Cardiology Department
-
Sofia, Sofia City Province, Bulgarien, 1527
- Rekrutierung
- University Hospital for Active Treatment Tsaritsa Joanna - ISUL | Cardiology Clinic
-
-
Veliko Tarnovo Province
-
Veliko Tarnovo, Veliko Tarnovo Province, Bulgarien, 5000
- Rekrutierung
- Multiprofile Hospital for Active Treatment Dr. Stefan Cherkezov | Base 1 - Cardiology Department
-
-
-
-
Lower Saxony
-
Hanover, Lower Saxony, Deutschland, 30625
- Noch keine Rekrutierung
- Medizinische Hochschule Hannover|Kardiologie und Angiologie
-
-
North Rhine-Westphalia
-
Bad Oeynhausen, North Rhine-Westphalia, Deutschland, 32545
- Noch keine Rekrutierung
- Herz-und Diabeteszentrum NRW|Elektrophysiologie/Rhythmologie
-
-
Thuringia
-
Altenburg, Thuringia, Deutschland, 04600
- Rekrutierung
- Klinikum Altenburger Land GmbH-Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin
-
-
-
-
Apulia
-
Acquaviva delle Fonti, Apulia, Italien, 70021
- Rekrutierung
- Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC
-
-
Lazio
-
Rome, Lazio, Italien, 00161
- Noch keine Rekrutierung
- Azienda Ospedaliero-Universitaria Policlinico Umberto I - Malattie Cardiovascolari
-
-
Lombardy
-
Milan, Lombardy, Italien, 20138
- Rekrutierung
- Centro Cardiologico Monzino S.p.A. - UO Scompenso e Cardiologia Clinica
-
-
The Marches
-
Torrette, The Marches, Italien, 60126
- Noch keine Rekrutierung
- Azienda Ospedaliero Universitaria Delle Marche - Clinica di Cardiologia e Aritmologia
-
-
-
-
-
Groningen, Niederlande, 9713 GZ
- Noch keine Rekrutierung
- Universitair Medisch Centrum Groningen
-
-
Limburg
-
Maastricht, Limburg, Niederlande, 6229 HX
- Noch keine Rekrutierung
- Maastricht UMC
-
-
-
-
Lesser Poland Voivodeship
-
Chrzanów, Lesser Poland Voivodeship, Polen, 32-500
- Noch keine Rekrutierung
- American Heart of Poland S.A. - MCSN, PAKS w Chrzanowie - Oddział Intensywnej Opieki Kardiologicznej
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-090
- Noch keine Rekrutierung
- USK nr 4 w Lublinie - Kliniczny Odd. Kardiologii, Reh. Kardio., Ch. Wew. z Pododdzialem Intensywnej Opieki Kardio.
-
-
Masovian Voivodeship
-
Grodzisk Mazowiecki, Masovian Voivodeship, Polen, 05-825
- Rekrutierung
- Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. sw. Jana Pawla II
-
-
Silesian Voivodeship
-
Bielsko-Biala, Silesian Voivodeship, Polen, 43-316
- Noch keine Rekrutierung
- American Heart of Poland S.A. - PAKS Centrum Kardiologii i Kardiochirurgii w Bielsku-Białej - Oddział Kardiologii
-
-
-
-
-
Budapest, Ungarn, 1122
- Rekrutierung
- Semmelweis Egyetem, Varosmajori Sziv- és Ergyogyaszati Klinika
-
-
Tolna County
-
Szekszárd, Tolna County, Ungarn, 7100
- Noch keine Rekrutierung
- Tolna Vármegyei Balassa János Kórház - I. Belgyógyászati Osztály: Kardiológia, Nefrológia
-
-
-
-
California
-
San Francisco, California, Vereinigte Staaten, 94143
- Zurückgezogen
- UCSF Advanced Heart Failure Comprehensive Care Center
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Noch keine Rekrutierung
- UCHealth University of Colorado Hospital - Cardiology
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Noch keine Rekrutierung
- Massachusetts General Hospital - Cardiology
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Rekrutierung
- Henry Ford Hospital - Cardiology
-
-
Minnesota
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Zurückgezogen
- M Health Fairview Heart Clinic - Maplewood
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27704
- Noch keine Rekrutierung
- Duke University Hospital - Cardiology
-
-
Texas
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Noch keine Rekrutierung
- Texas Health Heart and Vascular Specialists - Fort Worth
-
Tyler, Texas, Vereinigte Staaten, 75701
- Noch keine Rekrutierung
- CHRISTUS Trinity | Mother Frances Louis and Peaches Owen Heart Hospital - Electrophysiology Clinic
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participant must be 18 to 85 years of age inclusive, at the time of signing the informed consent.
- Participant is hemodynamically stable and does not require emergency cardioversion, as determined by the investigator.
- Participant has a current episode of atrial fibrillation (AF) ongoing for at least 3 hours and no more than 30 days at the time of randomization.
- Participant has an indication for electrical cardioversion of AF, as determined by the investigator according to standard clinical practice and national/institutional guidelines.
- At randomization, successful initiation and achievement of therapeutic levels of anticoagulation therapy, as well as completion of imaging evaluation for left atrial thrombi, as appropriate for the duration of the AF episode and risk for the participant according to national guideline and institution-specific routine practice.
- BMI within range [18 - 39.9] kg/m2.
- Contraceptive use by participants or participant partners should be consistent with the study protocol and local regulations regarding the methods of contraception for those participating in clinical studies.
- Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
- Willing and able to comply with the receipt, home use, and return of the continuous ECG recording device, as well as with the participation in scheduled telephone follow-up assessments.
Exclusion Criteria:
-
Current atrial flutter (AFL) or combined AF/AFL
-
Contraindication for electrical cardioversion on planned treatment day
-
Documented severely dilated left atrium (left atrial diameter, LAD >5 cm) measured by any modality within the 6 months prior to screening; if several values are available, the most recent one shall be reported. If left atrium diameter was not measured in the last 6 months or a major cardiovascular event occurred within the last 6 months, a new measurement must be done at screening
-
Unsuccessful conversion of current AF episode (pharmacologically or electrically)
-
Known severe valvular heart disease (e.g., severe mitral regurgitation, severe aortic stenosis)
-
Patients with NYHA Class ≥ III heart failure, or with active management of acute heart failure decompensation on treatment day.
-
History within the preceding 3 months prior to randomization of any of the following events, or any other significant cardiovascular event as judged by the investigator:
- Stroke
- Myocardial infarction
- Unstable angina pectoris or other signs of myocardial ischemia
- Cardiac surgery
- Transcatheter valve replacement
- Percutaneous coronary intervention (PCI)
- Coronary artery bypass graft (CABG) or other revascularization procedure
-
Severe renal impairment, i.e., estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² (using CKD-EPI formula) or requiring dialysis
-
Severe hepatic impairment, i.e. Child Pugh Class C
-
Use of anti-arrhythmic class I or III drugs within 5 half-lives before study drug administration (oral amiodarone in the previous 3 months)
-
Hypertension with SBP ≥ 180 mmHg or hypotension (SBP < 90 mmHg) at randomization (based on the second BP measurement)
-
Stressor-associated AF, i.e., in the setting of an acute and reversible stressor (e.g., cardiac surgery, myocarditis, endocarditis, sepsis, pneumonia, etc.). This includes ablation procedure within the preceding one month prior to randomization.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
|
intravenous (IV) treatment |
|
Experimental: BAY 3670549
|
intravenous (IV) treatment |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants with conversion from atrial fibrillation (AF) to sinus rhythm (SR), sustained for ≥1 minute, within 3 hours after start of study intervention administration, and prior to use of rescue therapy or other SoC for cardioversion
Zeitfenster: Up to 3 hours after start of administration of study intervention
|
AF = atrial fibrillation ; SR = sinus rhythm ; SoC = Standard of Care; |
Up to 3 hours after start of administration of study intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants who experienced Treatment Emergent Adverse Events (TEAE)s
Zeitfenster: From pre-dose* up to 48 hours after start of administration of study intervention
|
TEAE = Treatment Emergent Adverse Events; *Pre-dose: Within 4 hours prior to study intervention administration |
From pre-dose* up to 48 hours after start of administration of study intervention
|
|
Time to conversion from AF to SR as defined in the primary endpoint
Zeitfenster: Up to 3 hours after start of administration of study intervention
|
AF = atrial fibrillation SR = sinus rhythm; |
Up to 3 hours after start of administration of study intervention
|
|
Number of Participants in SR, at 3 hours after start of study intervention administration without prior use of rescue therapy or other SoC for cardioversion
Zeitfenster: Up to 3 hours after start of administration of study intervention
|
SoC = Standard of Care; |
Up to 3 hours after start of administration of study intervention
|
|
Plasma concentration of BAY 3670549 at the end of the infusion
Zeitfenster: From pre-dose* up to 8 hours after start of administration of study intervention
|
*Pre-dose: Within 4 hours prior to study intervention administration |
From pre-dose* up to 8 hours after start of administration of study intervention
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 22961
- 2025-523807-31-00 (Ctis)
- 2025 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .